Company Highlights Potential Role of MVA-Based Vaccine Technologies in Addressing Emerging Hemorrhagic Fever Threats, ...
WASHINGTON, April 16, 2025 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, administering doses to the ...
PRINCETON, N.J., May 21, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix (SNGX) or the Company), a late-stage biopharmaceutical company focused on developing and commercializing ...
ATLANTA, GA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire-- GeoVax Labs, Inc. (GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, ...
O. Rose Broderick reports on the health policies and technologies that govern people with disabilities’ lives. Before coming to STAT, she worked at WNYC’s Radiolab and Scientific American, and her ...
The Sabin Vaccine Institute has begun a Phase II trial in the US to evaluate its Marburg vaccine, with the first doses being given to subjects in Melbourne, Florida. The trial aims to enrol 200 ...
NPR's Scott Detrow talks with virologist Dr. Thomas Geisbert about the vaccine used in the Ebola outbreak of 2014 and the challenges for developing a vaccine for this current health emergency.
On Jan. 20, Tanzania declared an outbreak of the deadly Marburg virus disease in Biharamulo District in the northwestern part of the country’s Kagera Region. The announcement comes after public health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results